Day One Biopharmaceuticals (DAWN) IPO Opens 56% Higher

Today's IPO for Day One Biopharmaceuticals (NASDAQ: DAWN) opened for trading at $25 after pricing 10,000,000 shares of its common stock at a public offering price of $16.00 per share.

J.P. Morgan, Cowen and Piper Sandler are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

Day One is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Day One’s name was inspired by the “The Day One Talk”¹ that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with relapsed or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK). Day One is based in South San Francisco.

You May Also Be Interested In

• Day One Biopharmaceuticals (DAWN) PT Raised to $33 at Needham
• T-Mobile (TMUS) and EQT Announce JV to Acquire Lumos
• TD Cowen Reiterates Buy Rating on Day One Biopharmaceuticals (DAWN)